Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:57:52.415Z.
Calculation as of: 2026-10-06T14:57:52.415Z.
Quote observation: 2026-10-06T14:55:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f4a2befa970cab8c9956b6d8c2bddfeceb0bcb8bde8cbc5a5c0f5a0c0e258424
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $512.48M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $512.02M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $519.25M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.37M | N/A | N/A | N/A | N/A |
| Oculis Holding AG (OCS)vs › | $494.46M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $531.16M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $534.50M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $537.16M | N/A | 1.23% | 1.23% | 1.23% |
| Evolus, Inc. (EOLS)vs › | $482.72M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $545.59M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
